Diligence memo · auto-generated · as of July 2, 2026
Pyros Pharmaceuticals, Inc.
Pyros Pharmaceuticals, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Pyros Pharmaceuticals, Inc. operates in Biotech / Pharma, based in Parsippany.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Pyros Pharmaceuticals, Inc. has raised $880K in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $5.9M on 2020-03-31.
Most recent recorded round closed around 2022-03-21.
Valuation (modeled)modeled
Provath models Pyros Pharmaceuticals, Inc. at approximately $8.2M (range $246K–$55M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 3.86× the median modeled value of Pre-Seed Biotech / Pharma companies in 2022–2024 (28 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 12 months.
Last raise 4.3 yr ago; this sector typically re-raises about every 15 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 28% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 32% of those peers.
Closest niche peers: Gaingels Oct Bio LLC, Gaingels Alto Pharmacy LLC, Allander Biotechnologies, Inc., CyMon Bio, Inc., EOF Bio LLC.
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.